State Street’s Agile Therapeutics AGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-10,843
| Closed | -$21.1K | – | 4480 |
|
|
2023
Q4 | $21.1K | Hold |
10,843
| – | – | ﹤0.01% | 4336 |
|
|
2023
Q3 | $26.1K | Hold |
10,843
| – | – | ﹤0.01% | 4412 |
|
|
2023
Q2 | $32K | Buy |
+10,843
| New | +$57.7K | ﹤0.01% | 4527 |
|
|
2022
Q2 | – | Sell |
-145
| Closed | -$61K | – | 4996 |
|
|
2022
Q1 | $61K | Hold |
145
| – | – | ﹤0.01% | 4760 |
|
|
2021
Q4 | $142K | Hold |
145
| – | – | ﹤0.01% | 4482 |
|
|
2021
Q3 | $279K | Hold |
145
| – | – | ﹤0.01% | 4230 |
|
|
2021
Q2 | $386K | Sell |
145
-394
| -73% | -$1.3M | ﹤0.01% | 3957 |
|
|
2021
Q1 | $2.24M | Sell |
539
-37
| -6% | -$200K | ﹤0.01% | 3397 |
|
|
2020
Q4 | $3.31M | Buy |
576
+39
| +7% | +$230K | ﹤0.01% | 3156 |
|
|
2020
Q3 | $3.26M | Buy |
537
+13
| +2% | +$74.5K | ﹤0.01% | 3000 |
|
|
2020
Q2 | $2.91M | Buy |
524
+500
| +2,083% | +$2.6M | ﹤0.01% | 3023 |
|
|
2020
Q1 | $89K | Buy |
+24
| New | +$138K | ﹤0.01% | 3629 |
|
|
2017
Q2 | – | Sell |
-79
| Closed | -$512K | – | 3752 |
|
|
2017
Q1 | $512K | Buy |
79
+8
| +11% | +$40.2K | ﹤0.01% | 3379 |
|
|
2016
Q4 | $811K | Buy |
71
+1
| +1% | +$14K | ﹤0.01% | 3321 |
|
|
2016
Q3 | $976K | Buy |
70
+3
| +4% | +$42.8K | ﹤0.01% | 3201 |
|
|
2016
Q2 | $1.01M | Buy |
67
+17
| +34% | +$233K | ﹤0.01% | 3270 |
|
|
2016
Q1 | $617K | Buy |
50
+10
| +25% | +$129K | ﹤0.01% | 3313 |
|
|
2015
Q4 | $781K | Sell |
40
-1
| -2% | -$15.8K | ﹤0.01% | 3262 |
|
|
2015
Q3 | $550K | Buy |
41
+11
| +37% | +$195K | ﹤0.01% | 3316 |
|
|
2015
Q2 | $522K | Buy |
+30
| New | +$640K | ﹤0.01% | 3366 |
|
Other funds holding AGRX
State Street's AGRX Position: Q1 2024 in Review
State Street sold out of Agile Therapeutics (AGRX) in Q1 2024, closing a stake of 10,843 shares — an estimated $21.1K sold.
State Street first reported a position in AGRX in Q2 2015 and held it in 20 quarters. The position peaked at $3.31M in Q4 2020. 1 fund tracked by Wall St. Rank holds AGRX as of Q1 2024.
- State Street reported no remaining Agile Therapeutics position as of Q1 2024 after selling out during the quarter.
- State Street sold 10,843 Agile Therapeutics shares in Q1 2024, an estimated $21.1K.
- State Street first reported a position in Agile Therapeutics in Q2 2015 and held it in 20 quarters.
- State Street's Agile Therapeutics position peaked at $3.31M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Agile Therapeutics as of Q1 2024.
Based on State Street's 13F filing for Q1 2024, filed 15 May 2024.